Third Epidemiological Analysis of Nasopharyngeal Carcinoma in the Central Region of Japan from 2006 to 2015

Abstract

The present study aimed to clarify the incidence and clinical outcomes of nasopharyngeal carcinoma (NPC) in the Chubu region of Japan from 2006 to 2015, compared with previous reports. A retrospective analysis was conducted based on medical records from 40 hospitals located in the Chubu region in the central Japanese main island, with a population of around 22.66 million individuals. This study was designed in line with to two previous clinical studies into NPC conducted in the same area of Japan. We recruited NPC patients diagnosed in hospitals across this area over a 10-year period (2006–2015) using a questionnaire about sex, age, primary site, clinical symptoms, pathology, Union for International Cancer Control (UICC) staging, serological exam, treatment, and survival. A total of 620 NPC patients were identified. The age-standardized incidence of NPC from 2006 to 2015 was 0.27 per 100,000 individuals per year. There were no significant differences between this study and the previous two studies conducted in the same area of Japan. The five-year overall survival rate for all patients was 75.9%, while those for patients with stages I, II, III, and IVA were 97%, 91%, 79%, and 68%, respectively. The age-standardized annual incidence of NPC in the present study was 0.27 per 100,000 individuals per year, which was relatively low and stable. The five-year overall survival rate for all NPC patients was significantly improved in this decade compared with previous studies. The smoking rates in male and female NPC patients were 64.5% and 18.8%, respectively, thereby suggesting the involvement of smoking in the incidence of NPC.

Quality of Life as a Mediator between Cancer Stage and Long-Term Mortality in Nasopharyngeal Cancer Patients Treated with Intensity-Modulated Radiotherapy

“…Clinical studies reported that a high proportion of NPC patients were confirmed as AJCC stages III-IV at diagnosis [16][17][18]. Because cancer stage is an unchangeable factor and closely linked to a high mortality [3,4], this highlights the issue of how to prolong survival for advanced-stage NPC patients. QoL in recent studies was recommended as a vital outcome measure in clinical decision-making, especially for advanced-stage cancer patients [6,7,31,32].…”

“…In recent years, the medical application of intensity-modulated radiotherapy (IMRT) and optimization of chemotherapy strategies have prominently prolonged survival and lessened toxicities to normal tissues for patients with nasopharyngeal cancer (NPC) [1]. However, the 5-year survival rate for advanced-stage NPC (stages III and IV) is still at an ameliorable level, both in Asian areas (e.g., 23-79% in Japan and 60-79% in Taiwan) and European areas (e.g., 31-55% in Finland) [2][3][4]. Because the current anatomy-based staging system is insufficient for predicting therapeutic benefits or clinical prognosis [1], investigations that consider other clinical and non-clinical factors to help survival prediction are warranted.…”

Epstein‑Barr virus infection mediated TP53 and Bcl‑2 expression in nasopharyngeal carcinoma pathogenesis

“…Approximately 1.5% of cancer cases are associated with EBV infection amongst all cancer cases globally ( 11-13 ). NPC is primarily associated with EBV, and the EBV infection frequency in NPC is varied based on ethnic and geographical differences ( 23 ). Almost all the NPC cases from the endemic regions presented with EBV infection and in non-endemic regions, NPC was negative for EBV.…”

HUBUNGAN IgA ANTI-VCA EVB DENGAN GAMBARAN HISTOPATOLOGI PADA PENDERITA KARSINOMA NASOFARING

“…Hasil penelitian juga sejalan dengan studi yang dilakukan di Medan, puncak insidensi KNF terjadi pada kelompok usia 41-60 tahun dengan jumlah penderita sebesar 46,8% di Kota Medan [12]. Penelitian dengan melibatkan 620 penderita KNF dalam 10 tahun dari 2006 hingga 2015 di wilayah Chubu menunjukkan bahwa Jepang memiliki tingkat kejadian lebih tinggi pada pasien pria dalam kelompok usia 61-70 tahun [13].…”